Fed’s Powell opens door to potential rate cuts at Jackson Hole
On Monday, Truist Securities analyst David MacDonald increased the price target for Option Care Health (NASDAQ: NASDAQ:OPCH) shares, raising it to $40.00 from the previous $34.00, while maintaining a Buy rating. Currently trading at $34.10, the stock has shown impressive momentum with a 44% gain year-to-date. MacDonald’s optimistic stance is based on recent management meetings that highlighted a number of positive factors for the company. According to InvestingPro, two analysts have recently revised their earnings expectations upward for the upcoming period.
MacDonald pointed out the strong core demand trends driving the business, coupled with the attractive growth opportunities that lie ahead for Option Care Health. The company’s free cash flow (FCF) was also noted to be robust, which MacDonald believes will support ongoing accretive mergers and acquisitions (M&A) as well as share repurchase initiatives.
The analyst believes that Option Care Health’s business has been meaningfully de-risked following the Stelera period. With revenue growth of 16.2% in the last twelve months and an impressive five-year revenue CAGR of 17%, the company has demonstrated strong execution. He anticipates that normalized supply and the exit of competitors should support outsized growth in the acute segment by 2025. Additionally, MacDonald expects a potential halo effect stemming from these competitor exits.
MacDonald also highlighted Naven’s contribution to Option Care Health’s differentiated labor positioning. The further rollout of the advanced practitioner model is expected to create additional tailwinds for the company.
Reiterating the Buy rating, MacDonald’s revised price target reflects a positive outlook for Option Care Health’s future performance, underpinned by strong free cash flow and strategic growth initiatives.
In other recent news, Option Care Health Inc. reported a significant earnings beat for the fourth quarter of 2024. The company’s earnings per share (EPS) were $0.44, surpassing the forecasted $0.35, while revenue reached $1.35 billion, exceeding expectations of $1.27 billion. This performance marks a 19.7% revenue growth year-over-year and a 15.8% increase in adjusted EPS compared to the previous year. Additionally, Option Care Health expanded its operations by opening new pharmacies in New York City and Tampa, demonstrating its commitment to growth and innovation. The company also completed the acquisition of IntraMed Plus, enhancing its footprint in the Southeastern United States. Analysts have noted the company’s strong operational execution, with firms like William Blair and Jefferies engaging in detailed discussions during the earnings call. Looking ahead, Option Care Health projects 2025 revenue between $5.3 billion and $5.5 billion, with adjusted EBITDA ranging from $450 million to $470 million, despite anticipated challenges from Stelara biosimilar market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.